Faeth Therapeutics, Inc. Operating Lease Cost
Faeth Therapeutics, Inc. (FTH) reported Operating Lease Cost of $806.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-04
- Faeth Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $403.00K, a 0.00% change year-over-year.
- Faeth Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $403.00K, a 12.96% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $403.00K, a 12.96% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $403.00K, a 12.77% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, cost for fiscal 2025 was $1.67M, a 9.57% decline from fiscal 2024.
- Faeth Therapeutics, Inc. operating lease, cost for fiscal 2024 was $1.85M, a 2.95% increase from fiscal 2023.
- Faeth Therapeutics, Inc. operating lease, cost for fiscal 2023 was $1.80M, a 8.65% increase from fiscal 2022.
- Faeth Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.65M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $403.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $806.00K 10-Q · filed 2026-08-04 | $1.21M derived: sum of 3 quarters · filed 2026-08-04 | $1.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $403.00K 10-Q · filed 2026-05-15 | $806.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.21M derived: sum of 3 quarters · filed 2026-05-15 | $1.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $806.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.21M derived: sum of 3 quarters · filed 2026-08-04 | $1.67M 10-K · filed 2026-03-30 |
| 2025-09-30 | $403.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $806.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.27M 10-Q · filed 2025-11-14 | $1.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $403.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $866.00K 10-Q · filed 2026-08-04 | $1.33M derived: sum of 3 quarters · filed 2026-08-04 | $1.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $463.00K 10-Q · filed 2026-05-15 | $926.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.39M derived: sum of 3 quarters · filed 2026-05-15 | $1.85M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $925.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.39M derived: sum of 3 quarters · filed 2026-03-30 | $1.85M 10-K · filed 2026-03-30 |
| 2024-09-30 | $462.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $924.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.39M 10-Q · filed 2025-11-14 | $1.85M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $462.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $924.00K 10-Q · filed 2025-08-05 | $1.38M derived: sum of 3 quarters · filed 2025-08-05 | $1.84M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $462.00K 10-Q · filed 2025-05-06 | $922.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.38M derived: sum of 3 quarters · filed 2025-05-06 | $1.84M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $920.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.38M derived: sum of 3 quarters · filed 2025-03-28 | $1.80M 10-K · filed 2025-03-28 |
| 2023-09-30 | $460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $916.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.34M 10-Q · filed 2023-11-07 | $1.75M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $876.00K 10-Q · filed 2023-08-03 | $1.29M derived: sum of 3 quarters · filed 2023-08-03 | $1.70M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $420.00K 10-Q · filed 2023-05-09 | $833.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.25M derived: sum of 3 quarters · filed 2023-05-09 | $1.66M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $825.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.24M derived: sum of 3 quarters · filed 2023-03-29 | $1.65M 10-K · filed 2023-03-29 |
| 2022-09-30 | $412.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $826.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.24M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $828.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $414.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |